 |
| The year 2005 marked a significant turning point for India’s pharmaceutical sector with the introduction of product patent protection, in compliance with the WTO’s Agreement on Trade-Related aspects of Intellectual Property Rights (TRIPS). This transition ended India’s earlier regime that allowed only process patents, which had enabled the domestic industry to thrive as a global supplier of affordable generic medicines.
Two decades later, it is timely to critically examine the impact of this shift. How has the product patent regime influenced pharmaceutical innovation in India? Has it altered access to medicines scenario in the country? What has been its effect on the strategies of Indian pharmaceutical firms? And what policy challenges and opportunities lie ahead in balancing innovation incentives with public health imperatives? This Policy Roundtable aims to bring together distinguished experts from the government, academia, industry, and law to reflect on these issues. 📅 Date: Friday, 30 May 2025 |